newsfilter
← Latest News
Business Wire·

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

OS Therapies applies for meeting per FDA suggestion received on April 2, 2025 Based on prior FDA guidance, greater than 200 suitable matched lung metastatic osteosarcoma patient records identified from leading